TARS
Tarsus Pharmaceuticals Inc
TARS at a glance — five pillars scored 0–100 from real filed financials.
Overall: Unrated · 0/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Market Cap
$0.00
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
-13.0%
Interest Coverage
—
Current Ratio
3.74x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
0/100
Tarsus Pharmaceuticals Inc (TARS) is a small-cap company in the Pharmaceuticals industry, part of the Health Care sector of the S&P 500.
In its latest reported year it generated about $451.36M in revenue and posted a net loss of $66.42M.
Our model rates TARS Unrated (0/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
67.7%
Gross Margin
—
Operating Margin
-15.7%
Net Margin
-14.7%
ROE
—
Total Debt
$72.60M
Net Debt
-$29.59M
Net cash position
Net Debt / EBITDA
—
Debt / Equity
—
Leverage: debt-to-equity is n/a, with a current ratio of 3.7x. Detailed balance-sheet leverage is limited for this name. It carries roughly $72.60M of total debt against $102.19M of cash.
Operating CF
-$12.45M
Free Cash Flow
-$22.31M
FCF Margin
-4.9%
In the latest year Tarsus Pharmaceuticals Inc produced about -$12.45M of operating cash flow but negative free cash flow as it invested heavily. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
—
P/S
—
P/B
—
EV / EBITDA
—
TARS trades at n/a trailing earnings. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
The case for TARS:
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against TARS:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Tarsus Pharmaceuticals Inc is a small-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Unrated (0/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
TARS — frequently asked questions
Is TARS a good stock to buy?
We don't give buy or sell advice. Review Tarsus Pharmaceuticals Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does TARS's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Tarsus Pharmaceuticals Inc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for TARS calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this TARS analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell TARS. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.